Japan is the second largest drug market after the U.S., and Western drugmakers are giving it new attention as growth slows elsewhere. AstraZeneca has upped its bet there, paying Sumitomo Chemical about $102 million to buy full control of its Japanese subsidiary AstraZeneca KK.
Time is running out before generics descend on Nexium, the stomach drug that rakes in nearly $4 billion a year for AstraZeneca. And in an effort to conserve sales, the British drugmaker is going where it's gone once before: a direct-to-patient delivery program it hopes will keep customers in its grasp.
Two Big Pharma companies have inked new mobile-health deals with wireless service providers.
AstraZeneca has launched a website with hopes of opening up its R&D efforts to would-be collaborators, posting its compound bank and soliciting new ideas from academia, industry and government.
AstraZeneca CEO Pascal Soriot scored a big increase in bonus for 2013, but his total not only falls short of last year's, but pales by comparison with the biggest in Big Pharma. And his predecessor David Brennan's pay beats the total, too.
AstraZeneca is staring down the barrel of its Nexium patent loss, but it's doing its best to dodge the bullet. In a bid to keep patients hooked on the branded version of that purple pill, the company will sell Nexium to them directly--and at a discount.
AstraZeneca's MedImmune forged a new deal with Bioasis Technologies, licensing from the Vancouver, Canada, company its brain delivery platform aimed at overcoming challenges associated with the blood-brain barrier.
AstraZeneca is not long for northern England, locking down a buyer for its sprawling Alderley Park R&D campus as it prepares for a Cambridge, U.K., relocation.
The FDA's new guidelines for pill design may be the stick driving drugmakers to consider medication errors when blueprinting their drugs. But there's a carrot, too. With new tablet technologies, companies have more freedom to build their brands by making their pills distinctive.
AstraZeneca may get lucky with Nexium. That's thanks to the embattled Ranbaxy Laboratories, the Indian generics maker that could launch a copycat version May 27.